Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD51 | Q06609 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.34 |
| ▸ | GABRD | O14764 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.34 |
| ▸ | GABRE | P78334 | 1/20 | 0.34 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.34 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.34 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.34 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29952696 | 0.84 | CYP2A6 (0.44) | RAD51CA1CA2GABRPGABRD | |
| SCHEMBL1859259 | 0.84 | CYP2A6 (0.44) | RAD51CA1CA2GABRPGABRD | |
| SCHEMBL24025456 | 0.78 | SRC (0.35) | RAD51GSK3BPIN1ABCC9ABCC8 | |
| SCHEMBL7398707 | 0.77 | TSHR (0.40) | RAD51CYP2A6 | |
| SCHEMBL3872780 | 0.77 | GSK3B (0.39) | GSK3BCA1CA2ABCC9ABCC8 | |
| SCHEMBL29879019 | 0.76 | RAD51 (0.42) | RAD51CA1CA2GABRPGABRD | |
| SCHEMBL1232609 | 0.76 | RAD51 (0.42) | RAD51CA1CA2GABRPGABRD | |
| SCHEMBL15654620 | 0.73 | ERN1 (0.48) | CYP2A6 | |
| SCHEMBL1232330 | 0.73 | MEN1 (0.39) | GSK3BCA1CA2CA12CA9 | |
| SCHEMBL27552968 | 0.73 | GSK3B (0.37) | GSK3BCA2ABCC9ABCC8KCNJ11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082368-A1 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082368-A1 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | NGF, BDNF, NTRK2 | RAD51 3390/4885GSK3B 1764/4885CA1 847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.